Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection.
- Eric S Rosenberg
- Barney S Graham
- Ellen S Chan
- Ronald J Bosch
- Vicki Stocker
- Janine Maenza
- Martin Markowitz
- Susan Little
- Paul E Sax
- Ann C Collier
- Gary Nabel
- Suzanne Saindon
- Theresa Flynn
- Daniel Kuritzkes
- Dan H Barouch
DOIAbstract
An effective therapeutic vaccine that could augment immune control of HIV-1 replication may abrogate or delay the need for antiretroviral therapy. AIDS Clinical Trials Group (ACTG) A5187 was a phase I/II, randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of an HIV-1 DNA vaccine (VRC-HVDNA 009-00-VP) in subjects treated with antiretroviral therapy during acute/early HIV-1 infection. (clinicaltrials.gov NCT00125099)Twenty healthy HIV-1 infected subjects who were treated with antiretroviral therapy during acute/early HIV-1 infection and had HIV-1 RNA<50 copies/mL were randomized to receive either vaccine or placebo. The objectives of this study were to evaluate the safety and immunogenicity of the v...
.jpg%3Fwidth%3D300&w=3840&q=75)
Add to ORKG